GALT Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 23:00):

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases...

Stats
Šios dienos apimtis	173 828
Vidutinė apimtis	153 496
Rinkos kapitalizacija	213.57M
EPS	$0 ( 2024-04-04 )
Kita pelno data	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.66
ATR14	$0.0130 (0.38%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-24	Lewis Joel	Buy	1 000	Common Stock
2023-12-31	Czirr James C	Buy	0
2024-04-22	Czirr James C	Sell	21 323	Common Stock
2024-04-23	Czirr James C	Sell	3 677	Common Stock
2024-04-22	Freeman Kevin D	Buy	2 500	Common Stock

INSIDER POWER
24.13
Last 97 transactions
Buy: 4 256 891 \| Sell: 2 389 317

Tūris Koreliacija

Ilgas: 0.23 (neutral)

Trumpas: -0.75 (moderate negative)

Signal:(40.806) Neutral

Galectin Therapeutics Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
BRACU	0.946
KIN	0.945
ALGM	0.929
ACVA	0.929
NCAC	0.925
CLBT	0.921
PEGA	0.92
NSIT	0.92
AMYT	0.919
SRRA	0.919

10 Labiausiai neigiamai susiję koreliacijos
DCRC	-0.928
AHPI	-0.923
IMV	-0.922
NCBS	-0.921
TENX	-0.92
LAWS	-0.919
CFMS	-0.919
TSHA	-0.918
VWE	-0.917
SGLB	-0.914

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Galectin Therapeutics Inc Koreliacija - Valiuta/Žaliavos

0.12
( neutral )

0.70
( moderate )

0.00
( neutral )

0.64
( weak )

-0.24
( neutral )

-0.71
( moderate negative )

Galectin Therapeutics Inc Finansinės ataskaitos

Annual	2023
Pajamos:	$0
Bruto pelnas:	$-33 000.00 (0.00 %)
EPS:	$-0.680

FY	2023
Pajamos:	$0
Bruto pelnas:	$-33 000.00 (0.00 %)
EPS:	$-0.680

FY	2022
Pajamos:	$0
Bruto pelnas:	$-32 000.00 (0.00 %)
EPS:	$-0.660

FY	2021
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-0.520

Financial Reports:

No articles found.

Galectin Therapeutics Inc

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.